These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 3886352)

  • 1. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Clissold SP; Heel RC
    Drugs; 1985 Mar; 29(3):189-207. PubMed ID: 3886352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.
    Renner UD; Oertel R; Kirch W
    Ther Drug Monit; 2005 Oct; 27(5):655-65. PubMed ID: 16175141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002851. PubMed ID: 17636710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks A; Wasiak J
    Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD002851. PubMed ID: 21678338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis.
    Apfel CC; Zhang K; George E; Shi S; Jalota L; Hornuss C; Fero KE; Heidrich F; Pergolizzi JV; Cakmakkaya OS; Kranke P
    Clin Ther; 2010 Nov; 32(12):1987-2002. PubMed ID: 21118734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.
    Gordon CR; Gonen A; Nachum Z; Doweck I; Spitzer O; Shupak A
    J Psychopharmacol; 2001 Sep; 15(3):167-72. PubMed ID: 11565623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions].
    Offenloch K; Zahner G; Dietlein G; Franz I
    Arzneimittelforschung; 1986 Sep; 36(9):1401-6. PubMed ID: 3539128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting.
    Pergolizzi JV; Philip BK; Leslie JB; Taylor R; Raffa RB
    J Clin Anesth; 2012 Jun; 24(4):334-45. PubMed ID: 22608591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy].
    Becker G; Goossens H; Seemann K; Souchon F; Weitz T
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1881-5. PubMed ID: 6499689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
    Golding JF; Wesnes KA; Leaker BR
    Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scopolamine for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2004; (3):CD002851. PubMed ID: 15266468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus.
    Pyykkö I; Padoan S; Schalén L; Lyttkens L; Magnusson M; Henriksson NG
    Aviat Space Environ Med; 1985 Aug; 56(8):777-82. PubMed ID: 3929760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal hyoscine induced unilateral mydriasis.
    Hannon B; Jennings V; Twomey M; O'Reilly M
    BMJ Case Rep; 2012 Mar; 2012():. PubMed ID: 22605696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of transdermal therapeutics in perioperative care].
    Gentile A; Tran-Van D; Dardare E; Fritsch N; Benois A; Fontaine B
    Ann Fr Anesth Reanim; 2009 Apr; 28(4):311-20. PubMed ID: 19304449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alleviation of induced vertigo. Therapy with transdermal scopolamine and oral meclizine.
    Schmitt LG; Shaw JE
    Arch Otolaryngol Head Neck Surg; 1986 Jan; 112(1):88-91. PubMed ID: 3940518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.